Pfizer Inc (PFE): Drugs' Featured Winner Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.6%. By the end of trading, Pfizer rose 81 cents (2.8%) to $29.92 on average volume. Throughout the day, 40.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 31.7 million shares. The stock ranged in a price between $29.45-$30 after having opened the day at $29.45 as compared to the previous trading day's close of $29.11. Other companies within the Drugs industry that increased today were: Star Scientific ( STSI), up 14.8%, OxiGene ( OXGN), up 14.2%, BioTime ( BTX), up 12.6%, and Agenus ( AGEN), up 9.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $209.53 billion and is part of the health care sector. The company has a P/E ratio of 23.1, above the S&P 500 P/E ratio of 17.7. Shares are up 16.1% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Synergy Pharmaceuticals ( SGYP), down 17%, iBio ( IBIO), down 9.2%, Infinity Pharmaceuticals ( INFI), down 9%, and Tekmira Pharmaceuticals Corporation ( TKMR), down 6.5%, were all laggards within the drugs industry with Endo Health Solutions ( ENDP) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux